initial public offerings (IPOs) trading on American exchanges

Saturday, June 13, 2015

Adaptimmune Therapeutics (ADAP) began trading on the NASDAQ on 7 May 2015


Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its T-cell receptor platform. The Company has developed a platform that enables to identify cancer targets in the form of peptides, which are short sequences of amino acids, find and genetically engineer T-cell receptors (TCRs), and produce TCR therapeutic candidates for administration to patients. The Company's target peptides are NY-ESO-1 and MAGE A-10. The Company's affinity-enhanced TCR therapeutics targets the NY-ESO-1, or NY-ESO, cancer antigen. The Company has completed the Phase I/II clinical trials for its NY-ESO TCR therapeutic candidate, in patients with solid tumors and hematological malignancies, including synovial sarcoma, multiple myeloma, melanoma, ovarian cancer and esophageal cancer.


91 Park Drive
United Kingdom

Key stats and ratios

Q4 (Dec '14)2014
Net profit margin-127.81%-2100.84%
Operating margin-211.14%-2376.90%
EBITD margin--2335.49%
Return on average assets--44.15%
Return on average equity--

No comments:

Post a Comment